Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men

Clinical Cancer Research

Volumn 16, Issue 14, 2010, Pages 3539-3547

  Kwabi Addo, Bernard ^a   Wang, Songping ^a   Chung, Woonbok ^d   Jelinek, Jaroslav ^d   Patierno, Steven R ^c   Wang, Bi Dar ^c   Andrawis, Ramez ^c   Lee, Norman H ^c   Apprey, Victor ^b   Issa, Jean Pierre ^d   Ittmann, Michael ^e  

^a HOWARD UNIVERSITY CANCER CENTER   (United States)

^b HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANDROGEN RECEPTOR; GLUTATHIONE TRANSFERASE P1; OSTEONECTIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR NKX2.5; TRICHOSTATIN A;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PYROSEQUENCING; RARBETA2 GENE; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION;

AFRICAN AMERICANS; AGED; CELL LINE, TUMOR; DNA METHYLATION; EPITHELIAL CELLS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENES; GLUTATHIONE S-TRANSFERASE PI; HEALTH; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; OSTEONECTIN; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, RETINOIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TRANSCRIPTION FACTORS;

EID: 77954705069     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3342     Document Type: Article

References (22)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70.
2. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
3. Nelson WG, Yegnasubramanian S, Agoston AT, et al. Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci 2007;12: 4254-66.
4. Kwabi-Addo B, Chung W, Shen L, et al. Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res 2007;13:3796-802. (Pubitemid 47037584)
5. Hmadcha A, Bedoya FJ, Sobrino F, Pintado E. Methylationdependent gene silencing induced by interleukin 1β via nitric oxide production21. J Exp Med 1999;190:1595-604.
6. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4:143-53.
7. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
8. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81.
9. Bastian PJ, Yegnasubramanian S, Palapattu GS, et al. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol 2004;46:698-708. (Pubitemid 39488398)
10. Shu J, Jelinek J, Chang H, et al. Silencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Res 2006;66:5077-84. (Pubitemid 43844929)
11. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 2003;35:146-50. (Pubitemid 36828724)
12. Polnaszek N, Kwabi-Addo B, Peterson LE, et al. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res 2003;63:5754-60. (Pubitemid 37187471)
13. Kwabi-Addo B, Wang J, Erdem H, et al. The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res 2004;64:4728-35. (Pubitemid 38924514)
14. Ellinger J, Bastian PJ, Jurgan T, et al. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer12. Urology 2008;71:161-7. (Pubitemid 351173282)
15. Tokumaru Y, Harden SV, Sun DI, Yamashita K, Epstein JI, Sidransky D. Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma3. Clin Cancer Res 2004;10:5518-22. (Pubitemid 39100490)
16. Chung W, Kwabi-Addo B, Ittmann M, et al. Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling3. PLoS One 2008;3:e2079.
17. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000;85:60-7.
18. Freedland SJ, Isaacs WB. Explaining racial differences in prostate cancer in the United States: sociology or biology? Prostate 2005; 62:243-52.
19. Robbins CM, Hernandez W, Ahaghotu C, et al. Association of HPC2/ ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases. Prostate 2008; 68:1790-7.
20. Enokida H, Shiina H, Urakami S, et al. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer16. Int J Cancer 2005;116:174-81.
21. Woodson K, Hayes R, Wideroff L, Villaruz L, Tangrea J. Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among U.S. Blacks and Whites33. Prostate 2003;55:199-205.
22. Woodson K, Hanson J, Tangrea J. A survey of gene-specific methylation in human prostate cancer among black and white men27. Cancer Lett 2004;205:181-8. (Pubitemid 38230125)